There’s also the consent angle to all this, which Keira Bell’s case will open up. As I understand it, consent requires risks to be explained properly to patients so that their consent can be properly informed. Doctors have to explain material risks of a treatment they are offering, in an individualised way to each patient. So in GIDS‘ case, you wonder how they can explain risks adequately to their child patients and to parents, when there is so little evidence around risks from blockers, but there is evidence of lasting harm from blockers, and seems to be little available evidence of lasting benefit to patients from taking blockers? (As detransitioned women point to from their own experience).
The Medical defence union points to GMC guidance in place since 2009 that would require this approach to consent:
www.themdu.com/guidance-and-advice/guides/montgomery-and-informed-consent
This BMJ article argues that this standard discussion of risk should have been be applied to consents taken, as far back as 1999: www.bmj.com/content/357/bmj.j2224